香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任 何責任。 HONG KONG FERRY (HOLDINGS) COMPANY LIMITED 香港小輪（集團）有限公司 ( 於香港註冊成立之有限公司 ) (股份代號: 50) 《上市規則》之涵義 由於有關收購事項的其中一項或多項適用百分比率（定義見《上市規則》）超過 5%但全部均 低於 25%，收購事項構成本公司一項須予披露交易，並須遵守《上市規則》第 14 章項下的申 報及公告規定。 收購事項 董事會欣然宣佈，於二零二五年八月十九日，買方（本公司之全資附屬公司）與賣方及代理人 訂立臨時協議，據此，受限於及按照臨時協議的條款，買方同意收購及賣方同意出售該物業， 代價為港幣 260,000,000 元。臨時協議的主要條款載列如下： 臨時協議 1. 日期 二零二五年八月十九日 須予披露交易 收購物業 收購事項 董事會欣然宣佈，於二零二五年八月十九日，買方（本公司之全資附屬公司）與賣方及代理 人訂立臨時協議，據此，受 ...

Group 1: Policy Announcements - The Ministry of Finance, People's Bank of China, and Financial Regulatory Bureau released the "Implementation Plan for Personal Consumption Loan Interest Subsidy Policy," effective from September 1, 2025, to August 31, 2026, aimed at supporting personal consumption loans used for actual consumption [1] - The Ministry of Finance announced the "Loan Interest Subsidy Policy for Service Industry Operating Entities," which provides a 1% annual interest subsidy for loans to service industry entities, with a maximum loan amount of 1 million yuan per entity [1] Group 2: Company Financial Performance - Guizhou Moutai reported a revenue of 89.389 billion yuan for the first half of the year, a year-on-year increase of 9.1%, with a net profit of 45.403 billion yuan, up 8.89% [2] - Golden Dragon Fish achieved a revenue of 115.682 billion yuan in the first half, a 5.67% increase year-on-year, with a net profit of 1.756 billion yuan, marking a 60.07% growth [3] - China Unicom reported a revenue exceeding 200 billion yuan in the first half, a 1.5% year-on-year increase, with a total profit of 17.7 billion yuan, up 5.2% [3] - Pengding Holdings recorded a revenue of 16.375 billion yuan, a 24.75% increase year-on-year, with a net profit of 1.233 billion yuan, up 57.22% [3] - Zhenray Technology reported a revenue of 205 million yuan, a 73.64% increase year-on-year, with a net profit of 62.32 million yuan, up 1006.99% [3] Group 3: Corporate Actions - China Evergrande announced it will be delisted due to failure to meet the exchange's resumption requirements, with the last trading day set for August 22 [4] - China Shipbuilding announced the dissenting shareholders' buyout price at 30.02 yuan per share, with the closing price on August 12 at 38.50 yuan, indicating a premium of 28.25% [5] - China Heavy Industry announced a cash option for dissenting shareholders at 4.03 yuan per share, with the closing price on August 12 at 5.10 yuan, indicating a premium of 26.55% [5] - Quzhou Development disclosed a restructuring plan to acquire 95.46% of Xian Dao Electric Science and Technology through share issuance [5] - Golden Orange announced a restructuring plan to acquire 55% of Changchun Samit Optoelectronics through share issuance and cash payment [6] Group 4: Market Developments - The Shenzhen Stock Exchange will launch the Shenzhen AAA State-Owned Enterprise Credit Bond Index and the Shenzhen AAA Private Enterprise Credit Bond Index on August 15, focusing on high-grade credit bonds [2] - The National Medical Insurance Administration announced the preliminary review of the 2025 National Basic Medical Insurance Drug List, with 121 out of 141 drug names passing the initial review [1]

Group 1 - The stock price of *ST Bio (000504) closed at 11.91 yuan, down 5.02%, with a turnover rate of 1.1% and a trading volume of 36,100 shares, amounting to 43.0165 million yuan [1] - The net outflow of main funds was 12.0255 million yuan, accounting for 27.96% of the transaction amount, with large orders showing a net outflow of 12.9843 million yuan, which is 30.18% of the transaction amount [1] - The latest financial report for *ST Bio shows total operating revenue of 22.4536 million yuan, a year-on-year decrease of 13.55%, while net profit attributable to shareholders was 2.2186 million yuan, an increase of 19.92% [1] Group 2 - Nanhua Biological Pharmaceutical Co., Ltd. was established in 1991 and is primarily engaged in the pharmaceutical manufacturing industry, with a registered capital of 3,300.23098 million yuan and paid-in capital of 3,115.73901 million yuan [2] - The company has made investments in 11 enterprises and participated in 7 bidding projects, holding 46 trademark registrations and 4 patents [2]

Group 1: Regulatory and Policy Developments - Hangzhou Municipal Government has drafted the "Regulations on Promoting the Development of Embodied Intelligent Robot Industry" and is seeking public opinions, focusing on core technology areas such as intelligent models and core components [2] - The Ministry of Finance has released a draft for the implementation regulations of the "Value-Added Tax Law" to ensure its smooth implementation [2] Group 2: Company News and Financial Performance - Wanhu Chemical reported a revenue of 90.901 billion yuan for the first half of the year, a decrease of 6.35% year-on-year, with a net profit of 6.123 billion yuan, down 25.1% [3] - Satellite Chemical announced a revenue of 23.46 billion yuan for the first half of 2025, an increase of 20.93% year-on-year, with a net profit of 2.744 billion yuan, up 33.44% [3] - Aobi Zhongguang achieved a revenue of 435 million yuan in the first half of the year, a growth of 104.14%, and turned a profit with a net profit of 60.19 million yuan [3] - Fuda Co. reported a revenue of 937 million yuan for the first half of the year, a year-on-year increase of 30.26%, with a net profit of 146 million yuan, up 98.77% [4] - Nine Ding Investment plans to acquire a 53.29% stake in Nanjing Shenyuan Intelligent Technology for 213 million yuan, aiming to enhance its competitiveness in the humanoid robot sector [5] - Hikvision announced a cash dividend of 4 yuan per 10 shares to all shareholders [6] - *ST Bio is planning to acquire a 51% stake in Hunan Huize Biomedical Technology for cash, which will constitute a major asset restructuring [6] - Guangku Technology intends to acquire 100% of Suzhou Anjie Optical Technology, which is expected to constitute a major asset restructuring [6] - Fosun Pharma signed a licensing agreement with Expedition for the development and commercialization of a product outside of China, with potential payments totaling up to 6.45 billion yuan [7] Group 3: Market Insights and Trends - According to Everbright Securities, the market is expected to enter a new phase of upward momentum in the second half of the year, with a focus on consumption, technology, and dividend stocks [8] - Galaxy Securities noted that the steel industry is seeing a recovery in profitability, with leading companies reporting high profit growth and a focus on quality leaders in the sector [9]

Group 1 - The core point of the article is that *ST Bio (000504) is planning to acquire a 51% stake in Hunan Huize Biomedical Technology Co., Ltd. for cash, which will result in Huize becoming a subsidiary of the company, indicating a significant asset restructuring [2] - Huize is a professional CRO company focused on drug research and clinical evaluation, with over 85% of its revenue coming from clinical evaluation services, and has established long-term partnerships with over 300 pharmaceutical companies and research institutions [5] - The acquisition is expected to enhance *ST Bio's biopharmaceutical business, improve profitability, and increase the company's risk resistance, while also creating synergies through asset integration in clinical research and drug development [5][6] Group 2 - The transaction is anticipated to strengthen the overall growth and profitability of *ST Bio, aligning with the company's strategic development needs and fostering long-term sustainable growth [6] - Following the acquisition, *ST Bio's biopharmaceutical segment will include drug research and clinical evaluation services, enhancing its competitive edge [6] - *ST Bio has previously disclosed a performance forecast, expecting revenue between 49 million to 52 million yuan for the first half of 2025, representing a year-on-year decline of 7.68% to 13% [6]

Core Viewpoint - *ST生物 is planning to acquire a 51% stake in Hunan Huize Biomedical Technology Co., Ltd. for cash, which will make Huize a subsidiary and included in the consolidated financial statements. This transaction is expected to constitute a significant asset restructuring as per the regulations [1] Group 1: Company Overview - Huize Biomedical is a professional CRO company focused on drug research and clinical evaluation, providing services such as pharmaceutical research, clinical trials, and data management statistical analysis [1] - Prior to the acquisition, *ST生物 primarily engaged in two business segments: "biomedical" and "energy conservation and environmental protection," along with the production and sales of other biomedical-related products [1] Group 2: Strategic Intent - The acquisition aims to extend the biomedical segment of *ST生物, enhancing the profitability of its main business and improving its risk resistance capabilities [1] - There is a strong correlation between cell clinical transformation research and drug development, and the asset integration is expected to improve operational efficiency and create significant synergies [1]

格隆汇8月11日丨*ST生物（维权）(000504.SZ)公布，公司正在筹划以现金方式收购湖南慧泽生物医药 科技有限公司(简称"慧泽医药"或"标的公司")51%股权，本次交易完成后，慧泽医药将成为公司控股子 公司并纳入合并报表范围。 ...

Core Viewpoint - Hong Kong Ferry (Group) Limited's stock reached a new high of 4.930 HKD, reflecting a 1.65% increase from the previous trading day, indicating positive market sentiment and potential growth in the company's valuation [1] Company Overview - Hong Kong Ferry (Group) Limited was established in 1923 and has a long-standing history in Hong Kong. The company underwent a restructuring in 1989, changing its holding company name to "Hong Kong Ferry (Group) Limited" [1] - The primary business activities of the group include property development and investment, ferry services, shipbuilding, and related businesses. The company currently employs approximately 210 staff members [1] - In response to the future potential of healthcare, Hong Kong Ferry Group launched specialized medical and beauty services in 2022 as part of its diversification strategy [1] Financial Performance - As of August 8, the stock price reached 4.930 HKD, with a peak intraday price also at this level, marking a new high for nearly a year [1] - The net capital inflow for the day was 712,500 HKD, indicating positive investor interest despite unspecified outflows [1]

格隆汇8月1日丨香港小轮(集团)(00050.HK)宣布，公司将于2025年8月19日(星期二)举行董事会会议，藉 以(其中包括)批准刊发公司及其附属公司截至2025年6月30日止六个月的未经审核中期业绩公告及考虑 派发中期股息。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而 引致的任何損失承擔任何責任。 HONG KONG FERRY (HOLDINGS) COMPANY LIMITED 香港小 輪（集 團 ）有 限公司 香港，二零二五年八月一日 ( 於香港註冊成立之有限公司 ) (股份代號: 50) 於本公告日期，本公司之執行董事為林高演博士（主席）、李寧先生及李嘉豪先生；非執行董事為 歐肇基先生；以及獨立非執行董事為何厚鏘先生、黃汝璞女士、胡經昌先生及陳惠仁先生。 香港小輪（集團）有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司將 於二零二五年八月十九日（星期二）舉行董事會會議，藉以（其中包括）批准刊發本公 司及其附屬公司截至二零二五年六月三十日止六個月之未經審核中期業績公告及考慮 派發中期股息。 承董事會命 公司秘書 周東明 董事會召開日期 ...